Abstract
Novel tetrahydroisoquinolines have been developed as potent PPAR ligands. Evaluation of these compounds in PPARgamma responsive models of type 2 diabetes is described.
MeSH terms
-
Animals
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Humans
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / pharmacology*
-
Mice
-
Models, Molecular
-
PPAR gamma / agonists*
-
PPAR gamma / drug effects
-
Peroxisome Proliferator-Activated Receptors / antagonists & inhibitors
-
Rosiglitazone
-
Tetrahydroisoquinolines / chemistry
-
Tetrahydroisoquinolines / pharmacokinetics
-
Tetrahydroisoquinolines / pharmacology*
-
Thiazolidinediones / pharmacology
Substances
-
Blood Glucose
-
Hypoglycemic Agents
-
PPAR gamma
-
Peroxisome Proliferator-Activated Receptors
-
Tetrahydroisoquinolines
-
Thiazolidinediones
-
Rosiglitazone